[Allogeneic peripheral blood hematopoietic stem cell transplantation for post-operatively treating acute non-lymphocytic leukemia patient complicated with renal cell carcinoma: one case report].
The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic peripheral blood stem cell transplantation (allo-PBHSCT) for post-operative therapy of acute non-lymphocytic leukemia (ANLL) patient complicated with renal cell carcinoma (RCC). One ANLL patient complicated with RCC underwent an myeloablative HLA-identical relative allo-PBHSCT after RCC operation. The conditioning regimen consisted of total body irradiation, cyclophosphamide and cytarabine. Graft versus host disease (GVHD) prophylaxis regimen composed of cyclosporine A, myco-phenolate mofetil and short course of methotrexate. The results indicated that the patient achieved engraftment 16 days after transplantation with full donor-type chimerism detected by STR-PCR at 30 and 100 days after transplantation. No acute or chronic GVHD and any severe complication developed. As of March 2007, the patient remains without disease at follow-up of 44 months. In conclusion, allo-HSCT procedure is feasible and effective for post-operative therapy of ANLL patient complicated with RCC without severe toxicity.
Zhu
Hai-Yan
HY
Department of Hematology, The General Hospital of PLA, Beijing 100853, China.
DA
Wan-Ming
WM
Gao
Chun-Ji
CJ
Han
Xiao-Ping
XP
Wang
Shu-Hong
SH
Jing
Yu
Y
Bo
Jian
J
Jin
Hai-jie
HJ
Li
Meng
M
D000328:Adult; D002292:Carcinoma, Renal Cell / Q000601:surgery / Q000628:therapy*; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011184:Postoperative Period; D014184:Transplantation, Homologous